Predictive testing for Huntington disease: interpretation and significance of intermediate alleles
- PMID: 16965319
- DOI: 10.1111/j.1399-0004.2006.00668.x
Predictive testing for Huntington disease: interpretation and significance of intermediate alleles
Erratum in
- Clin Genet. 2007 Jan;71(1):99
Abstract
Direct mutation analysis for Huntington disease (HD) became possible in 1993 with the identification of an expanded CAG trinucleotide repeat as the mutation underlying the disease. Expansion of CAG length beyond 35 repeats may be associated with the clinical presentation of HD. HD has never been seen in a person with a CAG size of <36 repeats. Intermediate alleles are defined as being below the affected CAG range but have the potential to expand to >35 CAG repeats within one generation. Thus, children of intermediate allele carriers have a low risk of developing HD. Currently, the intermediate allele range for HD is between 27 and 35 CAG repeats. In this study, we review the current knowledge on intermediate alleles for HD including the CAG repeat range, the intermediate allele frequency, and the clinical implications of an intermediate allele predictive test result. The factors influencing CAG repeat expansion, including the CAG size of the intermediate allele, the sex and age of the transmitting parent, the family history, and the HD gene sequence and haplotype, will also be reviewed.
Similar articles
-
Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects.Nat Genet. 1993 Oct;5(2):174-9. doi: 10.1038/ng1093-174. Nat Genet. 1993. PMID: 8252043
-
Exploring the correlates of intermediate CAG repeats in Huntington disease.Postgrad Med. 2011 Sep;123(5):116-21. doi: 10.3810/pgm.2011.09.2466. Postgrad Med. 2011. PMID: 21904093 Review.
-
CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease.J Med Genet. 2013 Oct;50(10):696-703. doi: 10.1136/jmedgenet-2013-101796. Epub 2013 Jul 29. J Med Genet. 2013. PMID: 23896435
-
Inherited CAG.CTG allele length is a major modifier of somatic mutation length variability in Huntington disease.DNA Repair (Amst). 2007 Jun 1;6(6):789-96. doi: 10.1016/j.dnarep.2007.01.002. Epub 2007 Feb 12. DNA Repair (Amst). 2007. PMID: 17293170
-
Advances in Huntington's disease diagnostics: development of a standard reference material.Expert Rev Mol Diagn. 2006 Jul;6(4):587-96. doi: 10.1586/14737159.6.4.587. Expert Rev Mol Diagn. 2006. PMID: 16824032 Review.
Cited by
-
Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.Hum Mol Genet. 2014 Dec 1;23(23):6302-17. doi: 10.1093/hmg/ddu349. Epub 2014 Jul 4. Hum Mol Genet. 2014. PMID: 25035419 Free PMC article.
-
Genetic epidemiological characteristics of a Hungarian subpopulation of patients with Huntington's disease.BMC Neurol. 2021 Feb 18;21(1):79. doi: 10.1186/s12883-021-02089-9. BMC Neurol. 2021. PMID: 33602179 Free PMC article.
-
CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease.Neurobiol Dis. 2009 Nov;36(2):259-68. doi: 10.1016/j.nbd.2009.07.014. Epub 2009 Jul 24. Neurobiol Dis. 2009. PMID: 19632326 Free PMC article.
-
Experiences of predictive testing in young people at risk of Huntington's disease, familial cardiomyopathy or hereditary breast and ovarian cancer.Eur J Hum Genet. 2014 Mar;22(3):396-401. doi: 10.1038/ejhg.2013.143. Epub 2013 Jul 17. Eur J Hum Genet. 2014. PMID: 23860040 Free PMC article.
-
Intermediate CAG Repeats in Huntington's Disease: Analysis of COHORT.Tremor Other Hyperkinet Mov (N Y). 2012;2:tre-02-64-287-4. doi: 10.7916/D8FF3R2P. Epub 2012 Feb 2. Tremor Other Hyperkinet Mov (N Y). 2012. PMID: 23440000 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical